ASX-listed biotech PharmAust has been granted a core patent in Europe relating to the use of “aminoacetonitrile derivatives” as potent kinase inhibitors for the treatment of cancer. The patent is another positive step for Perth-based company in shoring up its global IP protections. It follows the granting of similar patents in key markets including the US, Australia and China.
14/09/2017 - 05:37
PharmAust secures key European anti-cancer patent
By Matt Birney
14/09/2017 - 05:37
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 202 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX